J. Franklin

发表

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.

V. Diehl, H. Müller-Hermelink, B. Dörken, 2003, The New England journal of medicine.

Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone.

R. Greil, R. Müller, N. Willich, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.

H. Eich, R. Müller, S. Sehlen, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How to restrict liver biopsy to high-risk patients in early-stage Hodgkin's disease

V. Diehl, J. Franklin, U. Paulus, 2000, Annals of Hematology.

Long-Term Follow-Up of BEACOPPescalated Chemotherapy in Patients with Advanced-Stage Hodgkin Lymphoma on Behalf of the German Hodgkin Study Group.

V. Diehl, J. Franklin, Engert Andreas, 2007 .

The tangible cost implications of a hospital outbreak of multiply-resistant salmonella

J. Franklin, P. Sockett, S. Tabaqchali, 1989, Epidemiology and Infection.

Interleukin-10 gene polymorphisms are associated with freedom from treatment failure for patients with Hodgkin lymphoma.

V. Diehl, T. Zander, J. Franklin, 2013, The oncologist.

Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF.

V. Diehl, N. Schmitz, J. Franklin, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group.

H. Eich, R. Müller, K. Hansemann, 2004, International journal of radiation oncology, biology, physics.

Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity?

V. Diehl, J. Raemaekers, J. Franklin, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment

J. Franklin, U. Fuhr, J. Wolf, 2020, Cancer medicine.

Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML

V. Diehl, J. Franklin, H. Tesch, 1999, Annals of Hematology.

Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials.

V. Diehl, J. Raemaekers, J. Radford, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group.

V. Diehl, J. Franklin, M. Beykirch, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.

H. Eich, R. Müller, V. Diehl, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease – Results of the German Hodgkin Study Group

V. Diehl, J. Franklin, M. Sieber, 2005, Leukemia & lymphoma.

Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression‐free survival

J. Franklin, A. Engert, I. Monsef, 2010 .

Lymphocyte-predominant Hodgkin's disease. An immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin Study Group.

V. Diehl, K. Hübner, J. Franklin, 1997, The American journal of pathology.

Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors.

V. Diehl, K. Hübner, J. Franklin, 2000, Blood.

Beacopp Chemotherapy for Advanced Hodgkin’s Disease: Results of Further Analyses of the HD9- and HD12- Trials of the German Hodgkin Study Group (GHSG).

R. Greil, V. Diehl, J. Franklin, 2004 .

Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis.

V. Diehl, J. Franklin, M. Sieber, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OP31 10-year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma

V. Diehl, J. Franklin, B. Pfistner, 2007 .

Nodular sclerosing Hodgkin disease: new grading predicts prognosis in intermediate and advanced stages.

V. Diehl, K. Hübner, J. Franklin, 2003, Blood.

Lymphocyte predominant Hodgkin's disease: pathology and clinical implication.

V. Diehl, J. Franklin, H. Tesch, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Classical Hodgkin's disease. Clinical impact of the immunophenotype.

V. Diehl, K. Hübner, J. Franklin, 1997, The American journal of pathology.

Lymphocyte predominant Hodgkin's disease--a workshop report. European Task Force on Lymphoma.

V. Diehl, J. Franklin, T. Marafioti, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Secondary M yeloid L eukemia a nd M yelodysplastic S yndromes in P atients T reated f or H odgkin's D isease: A R eport F rom t he German H odgkin's L ymphoma S tudy G roup

V. Diehl, J. Franklin, J. Wolf, 2003 .

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.

V. Diehl, H. Müller-Hermelink, B. Dörken, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HD12 Randomised Trial Comparing 8 Dose-Escalated Cycles of BEACOPP with 4 Escalated and 4 Baseline Cycles in Patients with Advanced Stage Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Lymphoma Study Group (GHSG), University of Cologne, D-50924 Cologne, Germany.

R. Greil, H. Eich, V. Diehl, 2006 .

Are Endoscopic Endpoints Reliable in Therapeutic Trials of Ulcerative Colitis?

J. Franklin, G. Terheggen, R. Mueller, 2013, Inflammatory bowel diseases.

Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.

R. Greil, V. Diehl, J. Franklin, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis

J. Franklin, C. Heussel, M. Hallek, 2011, Antimicrobial Agents and Chemotherapy.

Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)

W. Klapper, H. Döhner, J. Franklin, 2020, HemaSphere.

University of Southern Denmark Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG) Kutsch,

W. Klapper, H. Döhner, J. Franklin, 2020 .

Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.

V. Diehl, N. Harris, E. Jaffe, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of Pre-Endoscopic C-WATCH Score with Established Risk Assessment Tools in Patients with Upper Gastrointestinal Bleeding

J. Franklin, M. Bürger, T. Goeser, 2022, Digestive Diseases.

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

M. Hellmich, K. Döhner, M. Griesshammer, 2022, Annals of Hematology.

Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk.

J. Franklin, L. Specht, M. Paus, 2005, The Cochrane database of systematic reviews.

European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes.

V. Diehl, N. Harris, E. Jaffe, 2000, Blood.

Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the

V. Diehl, J. Franklin, V. Mailänder, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is escalated BEACOPP a standard therapy for advanced Hodgkin's disease?

V. Diehl, F. Cavalli, J. Franklin, 2000, The hematology journal : the official journal of the European Haematology Association.

Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group.

V. Diehl, N. Schmitz, J. Franklin, 1998, Blood.

Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.

V. Diehl, M. Scholz, J. Franklin, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.

M. Hellmich, J. Franklin, E. Smit, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.

V. Diehl, J. Franklin, J. Wolf, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.

V. Diehl, J. Franklin, J. Glossmann, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group.

V. Diehl, J. Franklin, M. Sieber, 2000, Blood.

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.

H Tesch, D Hasenclever, M Sieber, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma.

H. Amthauer, H. Eich, V. Diehl, 2008, Blood.

Lymphocyte-depleted classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin study group.

V. Diehl, J. Franklin, P. Borchmann, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease

B. Krug, V. Diehl, J. Franklin, 2001, Annals of Hematology.

Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease.

V. Diehl, H. Gerhartz, J. Franklin, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Study Group Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Prognostic factors and treatment outcome in primary progressive

V. Diehl, J. Franklin, M. Sieber, 2013 .

Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? German Hodgkin Lymphoma Study Group.

V. Diehl, J. Franklin, U. Paulus, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group.

V. Diehl, J. Franklin, M. Pfreundschuh, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma

V. Diehl, J. Franklin, A. Engert, 2008, Leukemia & lymphoma.

Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group.

H. Eich, R. Müller, V. Diehl, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.

M Sieber, A Engert, H. Eich, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials

M. Sydes, M. Federico, J. Franklin, 2017, Haematologica.

The successful treatment of multiresistant nonenteric salmonellosis with seven day oral ciprofloxacin.

J. Franklin, S. Tabaqchali, S. Barnass, 1990, The Journal of antimicrobial chemotherapy.

FromTreatmentFailure forPatientsWithHodgkin Lymphoma

V. Diehl, J. Franklin, N. Schoof, 2013 .

Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.

J. Franklin, A. Engert, I. Monsef, 2017, The Cochrane database of systematic reviews.

first-line chemotherapy in advanced-stage Hodgkin lymphoma progression or early relapse for patients with residual disease after Positron emission tomography has a high negative predictive value for

H. Amthauer, H. Eich, V. Diehl, 2013 .

The HD12 Panel of the German Hodgkin Lymphoma Study Group (GHSG): A Quality Assurance Program Based on a Multidisciplinary Panel Reviewing All Patients’ Imaging

H. Eich, R. Müller, V. Diehl, 2004, American journal of clinical oncology.

Current clinical trials for the treatment of advanced-stage Hodgkin's disease: BEACOPP.

V. Diehl, J. Franklin, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

V. Diehl, J. Franklin, P. Borchmann, 2014, Blood.

Effect of ceftazidime and gentamicin on the oropharyngeal and faecal flora of patients with haematological malignancies.

T. Lister, J. Franklin, S. Tabaqchali, 1990, The Journal of antimicrobial chemotherapy.

Mortality during Treatment of Patients with Advanced Hodgkin’s Lymphoma Undergoing Dose Escalated BEACOPP Chemotherapy: An Analysis of the German Hodgkin Study Group (GHSG).

V. Diehl, J. Franklin, B. Pfistner, 2005 .

Ruxolitinib Shows Efficacy in Patients with Newly-Diagnosed Polycythemia Vera: Futility Analysis of the Randomized Ruxo-BEAT Clinical Trial of the German Study Group for Myeloproliferative Neoplasms

M. Hellmich, K. Döhner, M. Griesshammer, 2019, Blood.

The HD 12 panel of the German Hodgkin lymphoma study group (GHSG) - a quality assurance program based on a multidisciplinary panel reviewing all patients’ imaging

R. Müller, V. Diehl, J. Franklin, 2001 .

Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease

V. Diehl, H. Gerhartz, K. Hübner, 1998 .

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma.

H. Amthauer, H. Eich, V. Diehl, 2008, Blood.